Andrew Stevens
Hoofd Techniek/Wetenschap/O&O bij ViRexx Medical Corp.
Profiel
Andrew Stevens is Vice President of Clinical/Regulatory for ViRexx Medical Corp.
Prior to joining ViRexx, he was Vice President of Product Development at Cytovax, Inc. Previously, he was Vice President of Clinical Research and Regulatory Affairs with ViRexx and Director of Clinical and Regulatory Affairs and Director of Clinical and Professional Affairs at Biomira, Inc. Dr. Stevens holds a BS in Pharmacy and a PhD in Bionucleonics.
Actieve functies van Andrew Stevens
Bedrijven | Functie | Begin |
---|---|---|
ViRexx Medical Corp.
ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Hoofd Techniek/Wetenschap/O&O | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
ViRexx Medical Corp.
ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Health Technology |